Suven Life Sciences Limited

Neuropsychiatric Disorders

Research activity is centered on agitation associated with dementia, with a specific focus on Alzheimer’s disease-related behavioural symptoms.

  • Agitation with Dementia of the Alzheimer’s Type
  • Behavioural and psychological symptoms of dementia
  • Memory loss-associated agitation

The sponsor’s clinical interest in this area reflects work aimed at addressing disruptive neuropsychiatric symptoms that affect patients living with cognitive decline.

Alzheimer’s Disease Symptom Management

Clinical research is directed toward symptom control in Alzheimer’s disease, especially the management of agitation and related behavioural disturbances.

  • Agitation severity
  • Physical aggression
  • Excessive motor activity
  • Verbal aggression

This therapeutic area highlights interest in improving the clinical burden associated with dementia-related behavioural symptoms.

Central Nervous System Therapeutics

The sponsor’s research portfolio includes central nervous system therapeutics aimed at conditions where neurobehavioural dysregulation is a major concern.

  • Neuropsychiatric symptom relief
  • Behavioural disturbance in dementia
  • Age-related cognitive disorders

Work in this domain aligns with treatment development for symptoms that complicate the care of people with neurodegenerative disease.

Clinical Development in Geriatric Neurology

Research efforts are focused on older adult populations affected by dementia and its behavioural manifestations.

  • Geriatric psychiatry
  • Dementia care
  • Behavioural symptom assessment

The therapeutic emphasis is on clinical questions relevant to ageing-related neurological disease and associated agitation symptoms.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on Masupirdine for Treating Agitation in Alzheimer’s Dementia Patients

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Croatia Poland